Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V330 vaccine in healthy adults
NCT06630117Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V330 in norovirus infection (15 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants with Solicited Injection Site Adverse Events at 7 days, Number of Participants with Solicited Systemic Adverse Events at 7 days and 6 more. Started Mar 2024; status: completed.
02
Drugs
V330
03
Conditions
norovirus infection
Beyond the preview
Go deeper on NCT06630117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06630117.